- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05125965
Contribution of Cardiac MRI in the Early Diagnosis of Myocarditis Induced by Immunotherapy (MEDIIMYO)
Anti-cancer immunotherapy, one of the therapeutic revolutions of recent years. It is based on the use of antibodies that block immune system checkpoints that have been hijacked by cancer cells to benefit themselves. Blocking these checkpoints, such as PD-1, unleashes the action of anti-cancer T cells that can then destroy the tumor. The efficacy of these targeted therapies is significant, with an average 40% response rate in patients with metastatic cancers.Immune checkpoint inhibitors (ICIs) are becoming a 1st line therapy in many oncology indications due to their therapeutic line in many oncology indications due to their favorable effect on the prognosis of various prognosis of various cancers Since checkpoints play a key role in controlling the intensity and duration of an immune response, their immune response, therefore, their inhibition exposes to adverse inflammatory or autoimmune effects inflammatory or autoimmune adverse effects that can be severe and sometimes lethal.Most side effects of ICIs occur within the first few months after initiation of treatment. The toxicity of immunotherapy is immunological, all organs including the heart can be including the heart, can be affected.
Cardiac autoimmune involvement in ICIs can involve the myocardium, pericardium, and/or vascular endothelium. These entities may be interrelated or, on the contrary, isolated.
In the last 5 years, the number of described cases of myocarditis associated with ICIstreatment has increased. Their incidence remains low, estimated between 0.5 and 2%. This probably represents the most serious cardiovascular complication, as the mortality attributed to it reaches almost 50%.
In recent years MRI has become very important in the noninvasive diagnosis of acute myocarditis. The latest update of the Lake Louise criteria in 2018 has thus confirmed cardiac MRI in its first place among noninvasive examinations for the diagnosis of myocarditis with a sensitivity of 87.5%, a specificity of 96.2%, and a positive predictive value of 97.2%.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Arshid Azarine, MD
- Phone Number: 01.40.94.27.17
- Email: aazarine@ghpsj.fr
Study Locations
-
-
-
Le Plessis Robinson, France, 92350
- Centre Chirurgical Marie Lannelongue
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients undergoing immunotherapy with an indication for cardiac MRI for suspected myocarditis or other cardiovascular complications
- Patient over 18 years of age
- Patient affiliated to a health insurance plan
- Patient who has given free, informed and oral consent
Exclusion Criteria:
- Contraindication to immunotherapy
- Pregnant or breastfeeding patient (if applicable)
- Contraindication to cardiac MRI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patient undergoing immunotherapy with an indication for cardiac MRI
Patient undergoing immunotherapy with an indication for cardiac MRI for suspected myocarditis or myocarditis or other cardiovascular complications
|
3 additional minutes to perform the MRI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cardiac MRI
Time Frame: 1 day
|
ejection fraction
|
1 day
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ID RCB : 2021-A01656-35
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocarditis
-
University Hospital, AntwerpNiguarda HospitalNot yet recruiting
-
Massachusetts General HospitalBristol-Myers SquibbRecruitingCancer | Myocarditis AcuteUnited States, Canada
-
Cardiol Therapeutics Inc.RecruitingAcute MyocarditisUnited States, Israel, Brazil, France, Canada
-
Montreal Heart InstituteCompleted
-
M.D. Anderson Cancer CenterCompletedMyocarditis AcuteUnited States
-
Mayo ClinicCompletedMyocarditisUnited States
-
Niguarda HospitalIstituto Di Ricerche Farmacologiche Mario Negri; Ministry of Health, Italy; University... and other collaboratorsRecruitingMyocarditis AcuteItaly, United States, Spain, Belgium, Slovenia, Finland, France, Sweden, Czechia, Denmark, Germany, Greece
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Samsung Medical CenterAsan Medical Center; Chonnam National University Hospital; Korea University Anam... and other collaboratorsCompletedMyocarditis AcuteKorea, Republic of
-
Assiut UniversityScience and Technology Development Fund (STDF)CompletedMyocarditis ViralEgypt
Clinical Trials on additional time for the MRI
-
Universitaire Ziekenhuizen KU LeuvenKU Leuven; Research Foundation FlandersCompleted
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; CSL Behring and other collaboratorsNot yet recruitingLiver CirrhosisFrance
-
Lahey ClinicVasSol®-Nova SoftwareWithdrawnIntracranial Arterial AneurysmUnited States
-
Mayo ClinicCompletedEvaluate the Role of Real-time Imaging in Needle Placement | Evaluate the Workflow and Effectiveness of Realtime Imaging Versus Standard MR ImagingUnited States
-
University Hospital, ToulouseCompleted
-
University Hospital, BordeauxCompleted
-
Fondation Ophtalmologique Adolphe de RothschildRecruitingPre and Post-arterial Recanalization Imaging of Central Retinal Artery Occlusions (CRAO) (I-RECANAL)Magnetic Resonance Imaging | Diagnosis | Prognosis | Retinal Artery Occlusion | EtiologyFrance
-
University Hospital, MontpellierDirection Générale de l'Offre de SoinsRecruitingPelvic Pain | Acute Abdominal PainFrance
-
Fondation Ophtalmologique Adolphe de RothschildCompletedMultiple Sclerosis | Demyelinating Diseases | Magnetic Resonance Imaging | Central Nervous System | BrainFrance
-
Wake Forest University Health SciencesOhio State University; University of Mississippi Medical CenterCompletedBone Marrow TransplantationUnited States